Introduction
Despite the development of successful therapeutic strategies, it has thus far been impossible to eradicate HIV in infected individuals receiving highly active antiretroviral therapy (HAART), mainly due to the persistence of HIV within infected resting CD4+ T cells. 1 -3 Although most of these cells are not likely to produce infectious HIV, a small fraction contain integrated HIV DNA that is capable of producing virus upon stimulation.
Previous studies demonstrated that reservoirs are established early during infection. Starting antiretroviral therapyduring primary infection provides significant benefits to HIV-infected patients in terms of reduction of viral reservoirs. 4, 5 During the chronic phase of HIV infection, the dynamics of the latent reservoir is complex and evolving, and the decay of reservoirs seems very slow over time on antiretroviral treatment. 6, 7 The level of HIV-1 DNA varies considerably among chronically infected patients, even those successfully treated with HAART for long periods of time. In this regard, it should be of interest to determine clinical, virological and immunological characteristics associated with obtaining a low HIV DNA.
Bringing HIV DNA to extremely low levels may permit treatment simplification in successfully treated patients 8 and influence the occurrence and level of viral rebound upon discontinuation of therapy. 9, 10 We conducted the present study to address the factors that influence the establishment of a low HIV DNA in chronically infected long-term treated patients (initiating treatment during the chronic phase of infection). 
Methods
This cross-sectional study involved a subset of patients in Pitié-Salpêtrière Hospital with sustained virological suppression (HIV RNA levels ,50 copies/ mL) after ≥6 months of HAART, in whom total DNA measurement was performed. Patients treated since early acute infection or receiving (or having received in the past) cancer chemotherapeutic/immunosuppressive agents (including interferon-a) were excluded from the study. Plasma samples were collected in EDTA tubes and stored at 2808C until quantification. Residual plasma viraemia was measured as previously described. 8 The HIV-1 DNA level in peripheral blood mononuclear cells (PBMCs) was quantified using a real-time PCR method as previously described. 11 Total cell DNA extracts were systematically tested in duplicate (quantification limit: 10 copies/PCR, i.e. 66 copies/10 6 PBMCs). Both univariate (unadjusted) and multivariate logistic regression models were used to search for predictive factors of the DNA outcome. Two cut-offs were considered in the logistic models: level of undetectability and the inferior quantile of the whole population. Variables associated with the outcome (P,0.1) were considered candidates for the final model. The final multivariate model was built using a stepwise procedure selecting the variables associated with the outcome. This study was approved by the ANRS AC11 Ethics Committee. This study is a cross-sectional retrospective study. Consents have been obtained under previous studies involving this work.
Results
Overall, 243 subjects with undetectable HIV-1 plasma RNA (,50 copies/mL) were included in the study. The characteristics of the patients are presented in Table 1 . The median age was 47 years and 72% (n¼173) were male. A total of 195 (80%) acquired HIV-1 infection by sexual contact (men having sex with men or heterosexual intercourse) and 12 (5%) via intravenous drug use. Data on HIV plasma viral loads before treatment were available in 212 of the 243 studied patients. In these patients, the median peak of viral load before treatment was 5.03 log 10 copies/ mL and the median CD4 nadir was 216 cells/mL. Patients had been treated for a median time of 9 years and had undetectable levels of plasma viraemia for a median time of 3.1 years (IQR 0.9-5.4). Total HIV DNA measurements (one test per patient) were performed during HAART (after ≥6 months of HAART). The median HIV DNA was 372 copies/10 6 PBMCs (Table S1 , available as Supplementary data at JAC Online), 47 patients had levels of HIV DNA below the limit of detection and 58 patients had a low HIV DNA level (corresponding to the inferior quantile of the whole population: ,100 copies/10 6 PBMCs). At the time of DNA measurement, 61% (n¼130/212) of patients had a baseline viral load ,1 copy/mL.
To assess whether clinical, immunological or virological parameters might be related to obtaining a low HIV DNA in this population, a logistic model was used (Table 2) . Because there is no standard to define a low HIV-1 DNA, two cut-offs were considered in the logistic model: level of undetectability (,66 copies/10 6 PBMCs) and the inferior quantile of the whole population (,100 copies/10 6 PBMCs) (Table S2 , available as Supplementary data at JAC Online). In univariate analysis, regardless of the cut-off used, a low level of HIV DNA was associated with a low HIV-1 RNA peak (P,0.0001), a viral load ,1 copy/mL (P¼0.0003 and P¼0.001, respectively), a low current CD8 Tcell count (P¼0.0256 and P¼0.0011, respectively) and a high current CD4/CD8 ratio (P¼0.0024 and P¼0.0052, respectively). When considering the cut-off ,100 copies/10 6 PBMCs, a low HIV DNA was also associated with a longer time spent with undetectable HIV-1 RNA (P¼0.0281) and a high CD4 T cell nadir (P¼0.0433). Other factors such as antiretroviral regimen types, length of time on HAART and duration of HIV-1 infection were not associated with levels of HIV-1 DNA. In a multivariate regression model, only a low HIV-1 RNA peak remained significantly associated with a low HIV DNA, regardless of the cut-off used. The absence of residual viraemia (,1 copy/mL) and a high CD4/CD8 ratio were associated with obtaining HIV DNA ,100 copies/10 6 PBMCs.
Discussion
Determining the factors associated with a low HIV DNA in chronically infected HAART-treated patients should be of great interest, as HIV DNA levels in treated patients have been shown to predict clinical outcome. A low HIV reservoir predicts a longer rebound time and predicts the viral set point in the case of treatment interruption. 9, 10 In addition, identifying a low HIV DNA could allow treatment simplification in treated patients with sustained control of viral replication, 8 although this question is hypothetical and should be further addressed by treatment simplification strategies (based on low-level reservoirs) to provide a clear answer. Furthermore, one study 12 described some patients whose viraemia remained controlled for several years after the interruption of HAART initiated during the primary infection (VISCONTI posttreatment controllers). In these patients, the control of viraemia following treatment interruption was associated with very low HIV reservoirs, suggesting that limiting the pool of infected cells Fourati et al.
is crucial for the successful control of viral replication in the absence of therapy. However, post-treatment control is a very rare situation, as other studies demonstrated that virus can rebound under HAART cessation even in patients with an extraordinarily low-level reservoir. 13 On the other hand, in the VISCONTI cohort, patients were treated very early during primary infection. It has been demonstrated that early treatment of HIV involves a bias towards infection of transitional and effector cells rather than central memory cells (the key reservoir for infection).
14 Therefore, early treated patients have distinct characteristics from chronically infected patients under HAART and it is difficult to extrapolate the reservoir size in acutely treated patients and in patients treated after widespread establishment of the reservoir.
In our study, the most relevant factor associated with obtaining a low viral blood DNA in chronically HAART-treated patients was the detection a low viral load peak before the initiation of treatment. This finding is consistent with recent data obtained from the SPARTAC study, 15 showing that the pre-therapeutic HIV viral load correlates with the HIV total DNA before and after the patients initiated treatment. In the SPARTAC study, patients started treatment during primary infection, whereas in our study, treatment was initiated during the chronic phase of infection, suggesting that regardless of the time of treatment initiation, the pre-therapeutic viral load is a major determinant of the residual reservoir.
Second, we found that a low HIV DNAwas associated, to a lesser degree and only when considering the cut-off of 100 copies/10 6 PBMCs, with the absence of residual viraemia and with a high CD4/ CD8 ratio, suggesting that the limited pool of infected resting cells is related to a stronger control of residual viraemia. In this hypothesis, the absence of residual viraemia avoids replenishment of the Univariate (unadjusted) and multivariate logistic regression models were used to search for predictive factors of the DNA outcome (two cut-offs were used: ,100 HIV DNA copies/10 6 PBMCs and ,66 HIV DNA copies/10 6 PBMCs). Variables associated with the outcome (P,0.1) were considered candidates for the final model. The final multivariate model was built using a stepwise procedure selecting the variables associated with the outcome. The global significance of the model is P,0.0001. Goodness-of-fit (Hosmer-Lemeshow) was P¼0.21 when the considered cut-off was ,100 copies/total DNA copies/10 6 PBMCs and P¼0.50 when the considered cut-off was ,66 copies/total DNA copies/10 6 PBMCs.
Low HIV-1 reservoir in treated patients 755 JAC reservoir, which in turn keeps the immune activation system to a low activation status. These observations reinforce the need to institute antiretroviral treatment early during infection; early treatment allows a better recovery of the cellular immune system and normalization of the CD4/CD8 ratio. Similar results were also observed in a previous study by Chun et al., 16 showing a significant inverse correlation between the frequency of CD4+ T cells carrying HIV-1 proviral DNA and the CD4/CD8 ratio in infected individuals receiving HAART.
This study has some limitations: the size of viral reservoir has been estimated using total HIV DNA in peripheral blood, the limit of detection of the proviral DNA measurements is quite high (but can be routinely used) and the distribution of the HIV reservoirs among the different subsets of CD4 T cells has not been evaluated. One further limitation is that it is a cross-sectional, observational, monocentric study. Data from larger multicentric cohorts are needed to better define the factors associated with low proviral DNA set points after long-term treatment. However, these results may be helpful to identify candidates for future trials aiming at a functional cure of HIV infection, since low total HIV DNA levels will most likely be a prerequisite of successful immunological control of HIV replication.
